Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, including its lead development candidate, CUDC-907 which is being investigated in clinical studies in patients with lymphomas and solid tumors. It is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, the Company has exclusive licenses to oral small molecule antagonists of the PD1 and VISTA pathways, including PDL1/VISTA antagonist CA-170, and oral small molecule antagonists of the PD1 and TIM3 pathways, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. CA-170 is currently undergoing testing in a Phase 1 trial in patients with advanced solid tumors and lymphomas. 

Type
Public
HQ
Lexington, US
Founded
2000
Size (employees)
58 (est)
Website
curis.com
Curis was founded in 2000 and is headquartered in Lexington, US
Report incorrect company information

Curis Office Locations

Curis has an office in Lexington
Lexington, US (HQ)
4 Maguire Rd
Show all (1)
Report incorrect company information

Curis Financials and Metrics

Curis Financials

Curis's revenue was reported to be $9.90 m in FY, 2017
USD

Revenue (Q1, 2018)

2.5 m

Net income (Q1, 2018)

(10.7 m)

EBIT (Q1, 2018)

(9.9 m)

Market capitalization (22-Jun-2018)

68.9 m

Closing share price (22-Jun-2018)

2.1

Cash (31-Mar-2018)

24.7 m

EV

83.9 m
Curis's current market capitalization is $68.9 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

15 m9.8 m7.9 m7.5 m9.9 m

Revenue growth, %

(34%)(20%)(4%)

General and administrative expense

14.1 m

R&D expense

45.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

7.2 m1.3 m4.8 m1.8 m1.7 m2.1 m2 m1.7 m1.7 m1.8 m2.1 m2.1 m2.5 m

General and administrative expense

2.8 m2.8 m2.9 m2.7 m3.5 m3.4 m2.8 m3.6 m3.4 m4.7 m3.5 m3.8 m4 m

R&D expense

121.9 k3.1 m3.3 m3.7 m4.7 m5.9 m4 m6.8 m8.8 m6.8 m13.5 m11.3 m8.3 m

Operating expense total

7.1 m6 m6.3 m6.5 m32.7 m9.5 m6.9 m10.5 m12.4 m29.5 m17.2 m15.2 m12.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

9.6 m7.7 m33.1 m26 m38.3 m

Accounts Receivable

1.5 m2 m2.1 m2.5 m3.1 m

Inventories

495.3 k489.8 k1.2 m1.3 m

Current Assets

60.2 m52.2 m85.5 m48.2 m64.3 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

13.8 m7.9 m10.2 m7.9 m23.5 m31.5 m28.7 m14.7 m8.6 m20.7 m42.4 m26.7 m24.7 m

Accounts Receivable

1.2 m1.4 m4.8 m1.8 m1.8 m2.1 m2.3 m1.7 m1.9 m1.9 m2.2 m2.2 m2.5 m

Current Assets

64.9 m59.6 m61 m57.1 m102.6 m102.1 m96.6 m75.8 m64.5 m56.6 m64.4 m54.4 m51.9 m

PP&E

467.5 k408.6 k439.4 k407.4 k364 k323.1 k315.5 k383.6 k451 k406 k410 k426 k390 k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(12.3 m)(18.7 m)(59 m)(60.4 m)(53.3 m)

Depreciation and Amortization

141.5 k155.1 k160.8 k193 k235 k

Inventories

Accounts Payable

Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(1.9 m)(5.6 m)(1.9 m)(5.6 m)(31.8 m)(8.1 m)(5.5 m)(9.4 m)(11.3 m)(28.3 m)(15.7 m)(10.7 m)

Depreciation and Amortization

53 k

Accounts Payable

2.8 m2.4 m2.8 m2.4 m2.6 m4.9 m3.9 m5.1 m5.9 m

Cash From Operating Activities

(10 m)
USDY, 2018

EV/EBIT

-8.5 x

EV/CFO

-8.4 x

Financial Leverage

4.2 x
Show all financial metrics
Report incorrect company information

Curis Online and Social Media Presence

Embed Graph
Report incorrect company information

Curis News and Updates

Global Histone Deacetylase 2 Market By Industry Analysis, Size, Share, Growth, Trends and Forecast 2018- 2025 : Global QYResearch

"Global Histone Deacetylase 2 Market Research Report 2018" is the latest addition to Global QYResearch industry research reports collection. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information